[vc_row][vc_column][vc_empty_space][/vc_column][/vc_row][vc_row][vc_column width=”1/2″][vc_column_text]Trial ID : NCT05043090
Kidney Cancer Type: Papillary
A study of combination durvalamab + savolitinib versus sunitinib or durvalamab alone in patients with papillary kidney cancer[/vc_column_text][vc_empty_space][vc_empty_space][vc_column_text]Basic Eligibility:
- Papillary kidney cancer
- Advanced kidney cancer that cannot be removed by surgery
- Genetic test required to confirm c-MET is involved in driving your cancer
- No prior treatment is allowed with any of the study drugs, or any other c-MET inhibitor (e.g. Cabozantinib)
[/vc_column_text][vc_empty_space][/vc_column][vc_column width=”1/2″][vc_column_text]Trial ID : NCT04987203
Kidney Cancer Type: Clear Cell
A study of tivozanib alone or in combination with nivolumab in patients with advanced kidney cancer[/vc_column_text][vc_empty_space height=”52px”][vc_empty_space][vc_column_text]Basic Eligibility:
- Clear Cell Kidney Cancer Only
- Advanced kidney cancer that cannot be removed by surgery
- Patients must have completed at least one line of prior immunotherapy (e.g. Pembrolizumab)
[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space][vc_empty_space][/vc_column][/vc_row]